About Carrie Cunningham, MD

Dr. Carrie Cunningham is an associate professor of surgery at Harvard Medical School, section head of the Endocrine Surgery Program at Massachusetts General Hospital, and a senior scientist at the Mass General Institute for Technology Assessment. She is the Association of Endocrine Surgeons research committee chair and executive council member and the past president of the Association of Academic Surgery. Her overarching research mission has been to improve the health and well-being of patients with benign and malignant endocrine-related diseases. She is the principal investigator of an NIH/NCI R-37 (R01-type merit award) award to examine the potential impact of new diagnostic technologies and personalized management strategies in patients with thyroid cancer using mathematical disease simulation modeling and an American Cancer Society Research Scholar Award to develop a patient-reported instrument to assess thyroid-cancer specific quality of life.

Clinical Interests:

Treats:

Locations

Mass General Surgery: Surgical Oncology
55 Fruit St.
Yawkey Center for Outpatient Care
7th Floor
Boston, MA 02114
Phone: 617-724-4000

Mass General Brigham Healthcare Center
102-104 Endicott St.
Danvers, MA 01923
Phone: 978-882-6621

Medical Education

  • MD, University of Michigan Medical School
  • Residency, New York Presbyterian Hospital
  • Fellowship, Massachusetts General Hospital

American Board Certifications

  • General Surgery, American Board of Surgery

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

In addition to her clinical practice which focuses on both benign and malignant thyroid, parathyroid, and adrenal disease, Dr. Cunningham has clinical and translational research interests including prediction and decision-analytic modeling to assess the comparative effectiveness and improve the quality of care of patients with endocrine-related disorders. Her current projects involve identifying appropriate and effective diagnostic, surgical, and surveillance strategies for patients with primary hyperaldosteronism and thyroid cancer. She obtained a Master of Public Health through the Harvard School of Public Health and completed her fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training in 2013. She continues as a senior scientist at the MGH Institute for Technology Assessment.

Publications

Reviews: Comments and Ratings